Familial Risk in a Case-Control Study on Breast Carcinoma

2015 ◽  
pp. 31-33
Author(s):  
Sylvia Richardson ◽  
Mariette Gerber ◽  
Henri Pujol
1990 ◽  
Vol 131 (6) ◽  
pp. 973-983 ◽  
Author(s):  
CURTIS METTLIN ◽  
IVANA CROGHAN ◽  
NACHIMUTHU NATARAJAN ◽  
WARREN LANE

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 592-592 ◽  
Author(s):  
L. Dumasia ◽  
C. Lobocki ◽  
A. Couturier ◽  
C. Lebeis ◽  
A. Drelichman

592 Background: Statin drugs, which enzymatically inhibit HMG CoA reductase, are used in the treatment of hypercholesterolemia. In vitro, statins have been shown to induce apoptosis and inhibit growth in breast cancer cell lines. Although controversial, recent clinical data has indicated that statins may have a chemopreventive effect against breast cancer. Our objective was to determine whether the long-term intake of statins (at least four years) demonstrates a protective effect against breast cancer as a primary endpoint. Methods: We conducted a retrospective, case-control study of female patients from a community-based hospital and medical center located in southeastern Michigan. Cases included patients diagnosed with invasive breast carcinoma between 1995–2005, as identified through the tumor registry. Controls were family practice patients (age > 35 years) randomly selected from a database generated for this same time-period. Patients completed a mailed questionnaire with information pertaining to their use of statins and other medications, as well as other breast cancer risk factors. Subjects (N = 521) and controls (N = 521) were case matched by age, race, and body mass index (BMI). Results: The mean age of patients was 62.9 (range 35–101 yrs.) with an average BMI of 27.5. Reported usage of statins for four or more years prior to diagnosis was 5.5% in breast cancer subjects and 6.9% in case-matched controls. Compared to nonusers, women who had been on statin therapy for four or more years prior to diagnosis were not found to have a decreased risk of breast cancer (odds ratio 0.78: 95% CI 0.47 - 1.31). Similarly, there was no difference in risk for nonusers versus those taking statins for <1 yr., 1–4 yrs., or ≥ 4 yrs. However, nulliparity, positive family history, report of any benign breast biopsy, and ≥ 5-year use of oral contraceptives (before age 30) were significantly associated with the occurrence of breast cancer (p < 0.002, Chi-square test). Conclusion: Although statins have been shown to inhibit growth in breast cancer cell lines in vitro, its effect in vivo has remained inconclusive. Our study did not demonstrate a significant protective effect against breast carcinoma in women who had ever taken statins, or those who had taken the drug for a minimum of four years. No significant financial relationships to disclose.


2016 ◽  
Vol 17 (1) ◽  
pp. 387-393 ◽  
Author(s):  
Iman Amrani ◽  
Nailya Bulatova ◽  
Abdalla Awidi ◽  
Al-Motassem Yousef ◽  
Jamal Masad Melhem ◽  
...  

2013 ◽  
Vol 50 (1) ◽  
pp. 65 ◽  
Author(s):  
SM Balasubramaniam ◽  
SB Rotti ◽  
S Vivekanandam

Cancer ◽  
2005 ◽  
Vol 103 (11) ◽  
pp. 2228-2235 ◽  
Author(s):  
Sonia M. Boyapati ◽  
Xiao Ou Shu ◽  
Yu-Tang Gao ◽  
Qiuyin Cai ◽  
Fan Jin ◽  
...  

2009 ◽  
Vol 49 (1) ◽  
pp. 47-51 ◽  
Author(s):  
Emma Larsson ◽  
Fredrik Granath ◽  
Jesper Swedenborg ◽  
Rebecka Hultgren

2014 ◽  
Vol 136 (10) ◽  
pp. 2378-2387 ◽  
Author(s):  
Valentina Assi ◽  
Nathalie J. Massat ◽  
Susan Thomas ◽  
James MacKay ◽  
Jane Warwick ◽  
...  

1994 ◽  
Vol 89 (1) ◽  
pp. 52-58 ◽  
Author(s):  
D. A. Brent ◽  
J. A. Perper ◽  
G. Moritz ◽  
L. Liotus ◽  
J. Schweers ◽  
...  

2003 ◽  
Vol 199 (1) ◽  
pp. 15-21 ◽  
Author(s):  
Syed Aziz ◽  
Shahid Pervez ◽  
Shaista Khan ◽  
Tariq Siddiqui ◽  
Naila Kayani ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document